CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 259 enrolled
Drug / intervention
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05143138
NCT05143138N/AActive

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries

W.L.Gore & Associates·observational·Posted Dec 3, 2021·Updated Aug 22, 2025

In Brief

An observational study evaluating GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis for Abdominal Aortic Aneurysm and Thoracic Aortic Aneurysm. Active but no longer recruiting, targeting 259 participants across 14 sites in 6 countries.

Detailed Summary

Multicenter, single-arm retrospective and prospective registry is being conducted to confirm the clinical performance and safety of GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis when used as a Bridging Stent with Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Italy, Netherlands, Norway, Spain, Sweden
Collaborators--

Timeline

N/AActive
202220232024202520262027
First PostedDec 3, 2021
Enrollment StartMar 23, 2022
Primary CompletionApr 30, 2024
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.6 years ago

Interventions

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesisdevice

Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent